We have identified a list of promising 505(b)2 opportunities, among which we have successfully developed formulations to the scale-up stage. The package is ready for investment and co-development partnerships.

  • One suspension injectable – TBF 2019
  • One oral 505(b)(2) – TBF 2019/early 2020
  • One oral suspension product – TBF 2019 
  • Two lyophilized injectables – 2019/early 2020
  • 3-4 lyophiles – planned for near future